Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes-progress and prospects. Int J Mol Sci. 2020;21(18):6842.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes–global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–11.

Article  PubMed  PubMed Central  Google Scholar 

Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–35.

Article  PubMed  PubMed Central  Google Scholar 

Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811–31.

Article  PubMed  PubMed Central  Google Scholar 

Landgraf R, Aberle J, Birkenfeld AL, et al. Therapy of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2019;127(Suppl 1):S73–92.

PubMed  Google Scholar 

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holst JJ, Gasbjerg LS, Rosenkilde MM. The role of incretins on insulin function and glucose homeostasis. Endocrinology. 2021;162(7):bqab065.

Article  PubMed  PubMed Central  Google Scholar 

Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: a novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complicat. 2022;36(12):108332.

Article  CAS  Google Scholar 

Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Mounjaro™. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro. Accessed 04 Feb 2024.

Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: a systematic update. Int J Mol Sci. 2022;23(23):14631.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.

Article  PubMed  Google Scholar 

Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.

Article  CAS  PubMed  Google Scholar 

Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.

Article  PubMed  Google Scholar 

Eli Lilly and Company. Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk [press release]. 2021. https://investor.lilly.com/news-releases/news-release-details/tirzepatide-results-published-lancet-show-superior-a1c-and-body#:~:text=At%2052%20weeks%2C%20the%20highest%20dose%20of%20tirzepatide,percent%20and%20weight%20gain%20of%201.9%20kg%20. Accessed 4 Feb 2025.

PR Newswire. Latest data from SURPASS trials demonstrate tirzepatide provided meaningful blood sugar reductions [press release]. 2021. Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss. https://www.prnewswire.com/news-releases/latest-data-from-surpass-trials-demonstrate-tirzepatide-provided-meaningful-blood-sugar-reductions-and-weight-loss-301322048.html. Accessed 4 Feb 2025.

PR Newswire. Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes [press release]. 2021. Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes. https://www.prnewswire.com/news-releases/tirzepatide-achieved-superior-a1c-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes-301239948.html. Accessed 4 Feb 2025.

ClinicalTrials.gov. A study of tirzepatide (LY3298176) versus insulin lispro (U100) in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6) (NCT04537923). 2022. https://clinicaltrials.gov/study/NCT04537923. Accessed 04 Feb 2024.

ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT) (NCT04255433). 2023. https://clinicaltrials.gov/study/NCT04255433. Accessed 04 Feb 2024.

Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103–11.

Article  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

Article  PubMed  Google Scholar 

Booth AM, Wright KE, Outhwaite H. Centre for Reviews and Dissemination databases: value, content, and developments. Int J Technol Assess Health Care. 2010;26(4):470–2.

Article  PubMed  Google Scholar 

Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Wiley; 2019. https://doi.org/10.1002/9781119536604.

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.

Article  PubMed  Google Scholar 

Dahl D, Onishi Y, Norwood P, Huh R, Patel H, Rodriguez A. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5). Diabetol Stoffwechs. 2022;17(Suppl 1):S23.

Google Scholar 

Wadhwa RR, Cascella M. Steady state concentration. Treasure Island (FL): StatPearls. 2023. https://www.ncbi.nlm.nih.gov/books/NBK553132/.

Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE). 2014. https://www.ncbi.nlm.nih.gov/books/NBK310366/.

Pedder H, Dias S, Bennetts M, Boucher M, Welton NJ. Modelling time-course relationships with multiple treatments: model-based network meta-analysis for continuous summary outcomes. Res Synth Methods. 2019;10(2):267–86.

Article  PubMed  PubMed Central  Google Scholar 

Pozzilli P, Norwood P, Jódar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024–31.

Article  CAS  PubMed  Google Scholar 

Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–12.

Article  PubMed  Google Scholar 

Guja C, Frías JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab. 2018;20(7):1602–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–17.